by
The adenoviral-vectored vaccines are made with the abortion-tainted HEK293 fetal cell lines.
(LifeSiteNews) – A new experimental “adenoviral-vectored” trial COVID vaccine that can be inhaled rather than injected and was in part developed with abortion-tainted cell lines will soon enter phase two of human trials in Canada.
The inhaled trial version of the COVID “trivalent adenoviral-vectored” vaccine is made in Canada and developed at McMaster University in Hamilton, Ontario. The new vaccine was created with funding from the Canadian federal government.
As noted in a press release on Friday, Karen Mossman, McMaster’s vice president of research, said the new aerosol version of the COVID shot was developed due to a “pressing need to develop new, more effective next-generation vaccine strategies.”
“As international leaders in respiratory mucosal immunity and vaccines, our researchers pivoted quickly with the arrival of the COVID-19 pandemic, drawing on an already strong inhaled vaccine research program focused on tuberculosis,” Mossman said.
Two versions of the “inhaled” COVID shot were developed in 2021, named “Tri:ChAd” and “Tri:HuAd,” both using some form of the spike protein from the COVID virus.
Concerningly, both versions were also made with the abortion-tainted HEK293 fetal cell lines.
McMaster recently announced that it had been given more than $8 million from the Canadian Institutes for Health Research (CIHR) so that the inhaled COVID shot can undergo phase two human trials.
According to McMaster, pre-clinical trials in animals have “already” shown that “the inhaled aerosol vaccine is far more effective at inducing protective immune responses than traditional injections.”
McMaster claims this is due to an inhaled version of the jab targeting the upper airways, where respiratory “viruses first enter the body.”
Phase one has already taken place in 30 adult volunteers. Of note is that the volunteers have had two shots of either the Pfizer or Moderna mRNA COVID jabs.
Phase two human trials of the McMaster COVID vaccine are set to start in the coming months and will involve up to 500 participants.
According to scientists at the Robert E. Fitzhenry Vector Laboratory at McMaster University, where the inhaled vaccines were made, their new version is “designed to target three parts of the virus,” as opposed to the current COVID shots which only target spike proteins.
The “inhaled” versions of the COVID shot is “built upon adenoviral vectors of human (Tri:HuAd) or chimpanzee (Tri:ChAd) origin, expressing three SARS-CoV-2 antigens (spike protein 1, full-length nucleocapsid protein, and truncated polymerase), and is suitable for respiratory mucosal delivery.”